Curis (CRIS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
22 May, 2026Executive summary
Special Meeting scheduled for June 25, 2026, to be held virtually for all shareholders.
Two main proposals: a reverse stock split and potential adjournment to solicit more votes if needed.
Board recommends voting FOR both proposals to maintain Nasdaq listing and flexibility.
Voting matters and shareholder proposals
Proposal 1 seeks approval for a reverse stock split at a ratio between 1-for-5 and 1-for-25, with the exact ratio and timing at the board's discretion.
Proposal 2 allows adjournment of the meeting to solicit additional proxies if insufficient votes are received for Proposal 1.
Only business described in the notice will be transacted at the meeting.
Shareholders of record as of May 21, 2026, are entitled to vote, with one vote per share.
Board of directors and corporate governance
Board retains authority to abandon the reverse stock split even after shareholder approval if deemed not in the best interest of the company.
Board will determine the exact split ratio and timing within six months of approval.
Latest events from Curis
- Reverse stock split and adjournment proposals were both approved by majority vote.CRIS
EGM 202625 Jun 2026 - Emavusertib shows superior efficacy and safety in lymphoma and AML, with broad expansion plans.CRIS
Corporate presentation5 Jun 2026 - Shareholders will vote on a reverse stock split to help maintain Nasdaq listing compliance.CRIS
Proxy filing5 Jun 2026 - All five shareholder proposals, including director elections and share increase, were approved.CRIS
AGM 202619 May 2026 - Q1 2026 net loss was $24.2M; cash runway extends into H2 2027, but viability is uncertain.CRIS
Q1 202613 May 2026 - Shareholders will vote on director elections, executive pay, auditor ratification, and a share increase.CRIS
Proxy filing22 Apr 2026 - Shareholders will vote on director elections, executive pay, auditor ratification, and a major share increase.CRIS
Proxy filing10 Apr 2026 - Emavusertib delivers deep, durable responses in blood cancers and advances toward registrational trials.CRIS
Corporate presentation1 Apr 2026 - Q4 2025 net income surged on Erivedge sale; PCNSL and CLL studies drive future growth.CRIS
Q4 202520 Mar 2026